Tongue carcinoma

Summary

Tongue carcinoma (MONDO:0850154) is a cancer and 11 clinical trials. Top therapeutic interventions include cisplatin, porfimer sodium, and temsirolimus. A subtype of tongue cancer — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Clinical trials: 11

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	tongue carcinoma
Mondo ID	MONDO:0850154
DOID	DOID:0080641
NCIT	C4824
UMLS	C0558353
MedGen	154320
GARD	0028068
Is cancer (heuristic)	yes

Disease family

This is a subtype of tongue cancer. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › nervous system cancer › sensory system cancer › tongue cancer › tongue carcinoma

Related subtypes (1): tongue squamous cell carcinoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 11.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	8
PHASE3	1
PHASE1	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00588770	PHASE3	ACTIVE_NOT_RECRUITING	Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
NCT04870762	PHASE2	RECRUITING	Customized 3D Printed Oral Stents During Head and Neck Radiotherapy
NCT00458978	PHASE2	COMPLETED	Cediranib Maleate in Treating Patients With Recurrent or Newly Diagnosed Metastatic Head and Neck Cancer
NCT01175980	PHASE2	COMPLETED	Vorinostat in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma
NCT01256385	PHASE2	COMPLETED	Temsirolimus With or Without Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer Who Did Not Respond to Previous Therapy
NCT02007200	PHASE2	COMPLETED	Soy Isoflavones in Preventing Head and Neck Cancer Recurrence in Patients With Stage I-IV Head and Neck Cancer Undergoing Surgery
NCT02068157	PHASE2	TERMINATED	Interstitial Photodynamic Therapy in Treating Patients With Recurrent Head and Neck Cancer
NCT02196168	PHASE2	TERMINATED	Cisplatin With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
NCT02254278	PHASE2	COMPLETED	Reduced-Dose Intensity-Modulated Radiation Therapy With or Without Cisplatin in Treating Patients With Advanced Oropharyngeal Cancer
NCT01254617	PHASE1	COMPLETED	Lenalidomide and Cetuximab in Treating Patients With Advanced Colorectal Cancer or Head and Neck Cancer
NCT00594724	Not specified	COMPLETED	Improving Therapeutic Outcomes in the Tongue Carcinoma Patient: Assessment of Adaptation Using Functional Magnetic Resonance Imaging and Diffusion Tensor Imaging

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
CISPLATIN	4	3
PORFIMER SODIUM	4	1
TEMSIROLIMUS	4	1
VORINOSTAT	4	1
CEDIRANIB MALEATE	3	1
SOY ISOFLAVONES	2	1